相似文献
1
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.
Front Neurol. 2022 Jan 31;12:805135. doi: 10.3389/fneur.2021.805135. eCollection 2021.
2
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.
Alzheimers Res Ther. 2020 Oct 29;12(1):137. doi: 10.1186/s13195-020-00703-5.
3
The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders.
J Alzheimers Dis Parkinsonism. 2018;8(4). doi: 10.4172/2161-0460.1000444. Epub 2018 Aug 10.
4
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.
5
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Alzheimers Res Ther. 2017 Jul 28;9(1):52. doi: 10.1186/s13195-017-0276-4.
6
Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings.
Alzheimers Res Ther. 2019 Mar 13;11(1):23. doi: 10.1186/s13195-019-0476-1.
7
α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15.
8
Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
J Neurol. 2016 Nov;263(11):2271-2277. doi: 10.1007/s00415-016-8259-0. Epub 2016 Aug 20.
9
Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.
J Neural Transm (Vienna). 2021 May;128(5):687-699. doi: 10.1007/s00702-021-02345-9. Epub 2021 Apr 29.
10
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
J Neural Transm (Vienna). 2018 Apr;125(4):615-650. doi: 10.1007/s00702-017-1821-9. Epub 2017 Dec 8.
引用本文的文献
1
Risk factors and predictors for Lewy body dementia: a systematic review.
NPJ Dement. 2025;1(1):20. doi: 10.1038/s44400-025-00022-2. Epub 2025 Aug 4.
2
Driving Therapeutic Innovation in Neurodegenerative Disease With Hydrogen Deuterium eXchange Mass Spectrometry.
Mol Cell Proteomics. 2025 Jun 20;24(8):101017. doi: 10.1016/j.mcpro.2025.101017.
3
RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases-advantages and limitations.
Front Neurol. 2025 May 27;16:1578252. doi: 10.3389/fneur.2025.1578252. eCollection 2025.
4
Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?
Nat Rev Neurol. 2025 May 12. doi: 10.1038/s41582-025-01090-x.
5
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's disease.
Mol Neurodegener. 2024 Aug 6;19(1):60. doi: 10.1186/s13024-024-00749-1.
6
Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology.
Alzheimers Dement. 2024 Apr;20(4):2564-2574. doi: 10.1002/alz.13704. Epub 2024 Feb 14.
7
Network Proteomics of the Lewy Body Dementia Brain Reveals Presynaptic Signatures Distinct from Alzheimer's Disease.
bioRxiv. 2024 Jan 24:2024.01.23.576728. doi: 10.1101/2024.01.23.576728.
8
Protein Biomarkers Shared by Multiple Neurodegenerative Diseases Are Calmodulin-Binding Proteins Offering Novel and Potentially Universal Therapeutic Targets.
J Clin Med. 2023 Nov 11;12(22):7045. doi: 10.3390/jcm12227045.
9
CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.
Nat Commun. 2023 Sep 13;14(1):5635. doi: 10.1038/s41467-023-41122-y.
10
Race and Ethnicity in Lewy Body Dementia: A Narrative Review.
J Alzheimers Dis. 2023;94(3):861-878. doi: 10.3233/JAD-230207.
本文引用的文献
1
Cutaneous α-synuclein is correlated with autonomic impairment in isolated rapid eye movement sleep behavior disorder.
Sleep. 2021 Dec 10;44(12). doi: 10.1093/sleep/zsab172.
2
Vagus Nerve and Stomach Synucleinopathy in Parkinson's Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the "Body-First" Hypothesis.
J Parkinsons Dis. 2021;11(4):1833-1843. doi: 10.3233/JPD-212733.
3
Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies.
J Alzheimers Dis. 2021;82(3):913-919. doi: 10.3233/JAD-210342.
4
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
Alzheimers Dement. 2021 Dec;17(12):1976-1987. doi: 10.1002/alz.12353. Epub 2021 May 13.
5
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.
EMBO Mol Med. 2021 Jun 7;13(6):e14022. doi: 10.15252/emmm.202114022. Epub 2021 May 5.
6
Consistent skin α-synuclein positivity in REM sleep behavior disorder - A two center two-to-four-year follow-up study.
Parkinsonism Relat Disord. 2021 May;86:108-113. doi: 10.1016/j.parkreldis.2021.04.007. Epub 2021 Apr 17.
7
In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.
Neurology. 2021 May 18;96(20):e2513-e2524. doi: 10.1212/WNL.0000000000011935. Epub 2021 Apr 9.
8
Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
Acta Neuropathol Commun. 2021 Apr 7;9(1):62. doi: 10.1186/s40478-021-01175-w.
9
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
Lancet Neurol. 2021 Mar;20(3):203-212. doi: 10.1016/S1474-4422(20)30449-X.
10
Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias.
Neurology. 2021 Apr 6;96(14):e1855-e1864. doi: 10.1212/WNL.0000000000011699. Epub 2021 Feb 16.
Zotero 插件